608 related articles for article (PubMed ID: 16960145)
1. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL).
Duvic M; Talpur R; Ni X; Zhang C; Hazarika P; Kelly C; Chiao JH; Reilly JF; Ricker JL; Richon VM; Frankel SR
Blood; 2007 Jan; 109(1):31-9. PubMed ID: 16960145
[TBL] [Abstract][Full Text] [Related]
2. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma.
Olsen EA; Kim YH; Kuzel TM; Pacheco TR; Foss FM; Parker S; Frankel SR; Chen C; Ricker JL; Arduino JM; Duvic M
J Clin Oncol; 2007 Jul; 25(21):3109-15. PubMed ID: 17577020
[TBL] [Abstract][Full Text] [Related]
3. Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma.
Crump M; Coiffier B; Jacobsen ED; Sun L; Ricker JL; Xie H; Frankel SR; Randolph SS; Cheson BD
Ann Oncol; 2008 May; 19(5):964-9. PubMed ID: 18296419
[TBL] [Abstract][Full Text] [Related]
4. Phase I and pharmacokinetic study of the oral histone deacetylase inhibitor vorinostat in Japanese patients with relapsed or refractory cutaneous T-cell lymphoma.
Wada H; Tsuboi R; Kato Y; Sugaya M; Tobinai K; Hamada T; Shimamoto T; Noguchi K; Iwatsuki K
J Dermatol; 2012 Oct; 39(10):823-8. PubMed ID: 22506596
[TBL] [Abstract][Full Text] [Related]
5. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; Cohen MH; Justice R; Pazdur R
Oncologist; 2007 Oct; 12(10):1247-52. PubMed ID: 17962618
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the long-term tolerability and clinical benefit of vorinostat in patients with advanced cutaneous T-cell lymphoma.
Duvic M; Olsen EA; Breneman D; Pacheco TR; Parker S; Vonderheid EC; Abuav R; Ricker JL; Rizvi S; Chen C; Boileau K; Gunchenko A; Sanz-Rodriguez C; Geskin LJ
Clin Lymphoma Myeloma; 2009 Dec; 9(6):412-6. PubMed ID: 19951879
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer.
Blumenschein GR; Kies MS; Papadimitrakopoulou VA; Lu C; Kumar AJ; Ricker JL; Chiao JH; Chen C; Frankel SR
Invest New Drugs; 2008 Feb; 26(1):81-7. PubMed ID: 17960324
[TBL] [Abstract][Full Text] [Related]
8. Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVA mycosis fungoides/Sézary syndrome.
Child F; Ortiz-Romero PL; Alvarez R; Bagot M; Stadler R; Weichenthal M; Alves R; Quaglino P; Beylot-Barry M; Cowan R; Geskin LJ; Pérez-Ferriols A; Hellemans P; Elsayed Y; Phelps C; Forslund A; Kamida M; Zinzani PL
Br J Dermatol; 2016 Jul; 175(1):80-8. PubMed ID: 26836950
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.
Garcia-Manero G; Yang H; Bueso-Ramos C; Ferrajoli A; Cortes J; Wierda WG; Faderl S; Koller C; Morris G; Rosner G; Loboda A; Fantin VR; Randolph SS; Hardwick JS; Reilly JF; Chen C; Ricker JL; Secrist JP; Richon VM; Frankel SR; Kantarjian HM
Blood; 2008 Feb; 111(3):1060-6. PubMed ID: 17962510
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
Kirschbaum M; Frankel P; Popplewell L; Zain J; Delioukina M; Pullarkat V; Matsuoka D; Pulone B; Rotter AJ; Espinoza-Delgado I; Nademanee A; Forman SJ; Gandara D; Newman E
J Clin Oncol; 2011 Mar; 29(9):1198-203. PubMed ID: 21300924
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma.
Kavanaugh SM; White LA; Kolesar JM
Am J Health Syst Pharm; 2010 May; 67(10):793-7. PubMed ID: 20479100
[TBL] [Abstract][Full Text] [Related]
12. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma.
Mann BS; Johnson JR; He K; Sridhara R; Abraham S; Booth BP; Verbois L; Morse DE; Jee JM; Pope S; Harapanhalli RS; Dagher R; Farrell A; Justice R; Pazdur R
Clin Cancer Res; 2007 Apr; 13(8):2318-22. PubMed ID: 17438089
[TBL] [Abstract][Full Text] [Related]
13. Vorinostat for refractory or relapsing epidermotropic T-cell lymphoma: a retrospective cohort study of 15 patients.
Kogge A; Volteau C; Saint-Jean M; Peuvrel L; Brocard A; Knol AC; Renaut JJ; Dréno B; Quéreux G
Acta Derm Venereol; 2015 Jan; 95(1):72-7. PubMed ID: 24806744
[TBL] [Abstract][Full Text] [Related]
14. FDG-PET/CT for the evaluation of response to therapy of cutaneous T-cell lymphoma to vorinostat (suberoylanilide hydroxamic acid, SAHA) in a phase II trial.
Kuo PH; Carlson KR; Christensen I; Girardi M; Heald PW
Mol Imaging Biol; 2008; 10(6):306-14. PubMed ID: 18665425
[TBL] [Abstract][Full Text] [Related]
15. Vorinostat in cutaneous T-cell lymphoma.
Duvic M; Vu J
Drugs Today (Barc); 2007 Sep; 43(9):585-99. PubMed ID: 17940636
[TBL] [Abstract][Full Text] [Related]
16. Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma.
Watanabe T; Kato H; Kobayashi Y; Yamasaki S; Morita-Hoshi Y; Yokoyama H; Morishima Y; Ricker JL; Otsuki T; Miyagi-Maesima A; Matsuno Y; Tobinai K
Cancer Sci; 2010 Jan; 101(1):196-200. PubMed ID: 19817748
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma.
Richardson P; Mitsiades C; Colson K; Reilly E; McBride L; Chiao J; Sun L; Ricker J; Rizvi S; Oerth C; Atkins B; Fearen I; Anderson K; Siegel D
Leuk Lymphoma; 2008 Mar; 49(3):502-7. PubMed ID: 18297527
[TBL] [Abstract][Full Text] [Related]
18. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma.
Duvic M; Vu J
Expert Opin Investig Drugs; 2007 Jul; 16(7):1111-20. PubMed ID: 17594194
[TBL] [Abstract][Full Text] [Related]
19. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer.
Vansteenkiste J; Van Cutsem E; Dumez H; Chen C; Ricker JL; Randolph SS; Schöffski P
Invest New Drugs; 2008 Oct; 26(5):483-8. PubMed ID: 18425418
[TBL] [Abstract][Full Text] [Related]
20. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
